Search Results

Dendreon Pharmaceuticals and Shoreline Biosciences announced an alliance to advance the future of iPSC-derived cellular therapies.

Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, is pleased to announce the appointment of Sherry Saurini as Vice President of Quality, effective August 23, 2021.

Atrion Corporation (NASDAQ: ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million.

Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, has partnered with Grant Hill, seven-time NBA All-Star and sports broadcaster, to launch Start Strong, a new initiative to help individuals make decisions with health in mind.

Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, has established and invested in its new contract manufacturing and services division to bring late-stage clinical assets through to commercialization.

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”) today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024.